Urinary Tract Infections

Rather than killing bacteria, acetone/hydroalcoholic rhizome extracts reduced adhesion of uropathogenic E. coli to human T24 bladder cells in vitro (no cytotoxicity); the active molecule is a hexadecyl coumaric-acid ester ^{8,9Reference 8Beydokhti et al. · 2017In vitroHexadecyl coumaric acid ester from the rhizomes of Agropyron repens with antiadhesive activity against uropathogenic E. coli — in vitroView study →Reference 9Rafsanjany et al. · 2013In vitroAntiadhesion as a functional concept for protection against uropathogenic E. coli: in vitro studies with traditionally used plantsView study →}. The only clinical data are an uncontrolled multicentre post-marketing surveillance of an Agropyron fluid extract in UTI/irritable bladder ^{10Reference 10Hautmann et al. · 2000ObservationalFluid extract of Agropyron repens for urinary tract infections or irritable bladder: multicentric post-marketing surveillance — observational}.

The active ester is a minor lipophilic constituent poorly extracted into tea, and no controlled human UTI trial exists.

Cryptolepis is the herb West African practitioners reach for as a systemic antibacterial and was traditionally used for urinary infection, but the entire evidence base is in vitro: ethanolic and solvent root fractions inhibit a broad Gram-positive/Gram-negative panel, and isolated cryptolepine is directly bactericidal against organisms including Staphylococcus aureus via membrane disruption and DNA intercalation ^{11,12,13Reference 11Mills-Robertson et al. · 2012In vitroIn vitro antimicrobial activity of ethanolic fractions of Cryptolepis sanguinolenta — in vitroView study →Reference 12Paulo et al. · 1994In vitroIn vitro antibacterial screening of Cryptolepis sanguinolenta alkaloids — in vitroView study →Reference 13Sawer et al. · 2005In vitroThe killing effect of cryptolepine on Staphylococcus aureus — in vitroView study →}.

No clinical trial has tested cryptolepis for UTI or any bacterial infection, and the most bactericidal fraction (chloroform) is not the traditional water decoction.

Goldenrod is a pharmacopoeial urinary herb: the German Commission E and the EMA/HMPC approve the aerial parts for irrigation (“flush”) therapy of the lower urinary tract ^{14,15Reference 14EMA/HMPC · 2008ReviewCommunity herbal monograph on Solidago virgaurea L., herba — traditional-use regulatory monographReference 15Blumenthal · 1998ReviewSolidaginis virgaureae herba (European goldenrod herb) — German Commission E approved monograph (irrigation therapy, lower urinary tract) — review}. The rationale is well-characterised preclinically — an aquaretic diuretic action (flavonoid fractions raised rat urine output 57–88% while lowering Na/K excretion, the hallmark of an aquaretic) ^{16,17Reference 16Chodera A et al. · 1991AnimalEffect of flavonoid fractions of Solidago virgaurea L. on diuresis and levels of electrolytes — in vivo rat studyView study →Reference 17Chodera A et al. · 1985AnimalDiuretic effect of the glycoside from a plant of the Solidago L. genus — in vivo animal studyView study →}, anti-adhesion/anti-biofilm activity against uropathogens ^{18Reference 18Fursenco C et al. · 2020Systematic reviewSolidago virgaurea L.: A Review of Its Ethnomedicinal Uses, Phytochemistry, and Pharmacological Activities — systematic reviewView study →}, and direct, insurmountable M2/M3 muscarinic antagonism on human bladder strips that offers a plausible route to easing urinary urgency ^{19Reference 19Borchert VE et al. · 2004In vitroExtracts from Rhois aromatica and Solidaginis virgaurea inhibit rat and human bladder contraction — in vitro tissue-bath and muscarinic receptor studyView study →}.

There is no single-herb human trial: every clinical study uses a fixed multi-herb product, and a 2026 open-label RCT (n=60) of a five-herb complex containing goldenrod was inferior to tamsulosin on urinary-symptom scores in ureteral-stent patients ^{20Reference 20Gallo G et al. · 2026RCTA randomized controlled trial comparing alpha-blocker (tamsulosin) and a phyto-complex (Solidago virga-aurea, Phyllantus niruri, Epilobium angustifolium, Peumus boldus and Ononis spinosa) in the treatment of ureteral stent-related symptoms — randomised controlled trial (combination product)View study →}. Effects depend on preparation and subspecies; use is short-term and not a substitute for antibiotics in a systemic infection.

A pharmacopoeial ‘urinary antiseptic + diuretic’ of long standing (British Pharmacopoeia, eclectic and South African use). Buchu’s one direct antimicrobial test was essentially negative, so the use rests on tradition rather than demonstrated antibacterial action.

Cashew is used traditionally for urinary disorders. Its antimicrobial data are general rather than specific to urinary infection.

A classic pharmacopoeial urinary and diuretic herb. No study has measured urine output or any renal endpoint.

The urinary-antiseptic reputation is traditional and has only in-vitro backing: various Equisetum species show moderate-to-strong activity against gram-positive bacteria, with a 2018 study reporting antibacterial activity alongside oxidative-stress and inflammation modulation ^{21Reference 21Pallag et al. · 2018In vitroEquisetum arvense L. extract induces antibacterial activity and modulates oxidative stress, inflammation — in vitroView study →}, and a five-species Serbian screen finding most tested organisms sensitive to some degree ^{22Reference 22Milovanović et al. · 2007In vitroAntioxidant, antimicrobial and genotoxicity screening of hydro-alcoholic extracts of five Serbian Equisetum species — in vitroView study →}.

Activity is inconsistent across species, solvents and strains; there is no clinical confirmation that oral horsetail reaches antibacterial concentrations in the urinary tract, and gram-negative uropathogens (the main UTI cause) are poorly covered. The diuretic “flushing” rationale is human-supported ^{23Reference 23Carneiro et al. · 2014RCTRandomized, double-blind clinical trial to assess the acute diuretic effect of Equisetum arvense (field horsetail) in healthy volunteers — randomised controlled trialView study →} but is not itself an anti-infective mechanism.

Urinary complaints are a core traditional use of jatobá. It has no experimental test against uropathogens; its antimicrobial data are against unrelated organisms.

A signature traditional urinary antiseptic and diuretic. Its antimicrobial data are in vitro, at concentrations far above achievable doses. Juniper is taken short-term, with caution where the kidneys are involved.

A traditional demulcent for cystitis and urethritis that soothes irritated urinary mucosa; its antibacterial data are gram-positive only and don’t cover the gram-negative organisms of a typical UTI, so its role is soothing rather than antimicrobial.

Historical Western and folk use lists urinary-tract infections among pine’s applications. There is no urinary trial; the genus’s in-vitro antimicrobial activity is the only mechanistic hint.

Eclectic and BHP practice used saw palmetto for genito-urinary catarrh, cystitis and urinary antisepsis. There is no antimicrobial or UTI research; its evidence base is in BPH.

A traditional aromatic antimicrobial. The antibacterial data are all in vitro at essential-oil concentrations, not drinkable doses, and there is no UTI trial.

The mechanism is well mapped — arbutin is hydrolysed to hydroquinone and >60% of an oral dose is recovered in urine as hydroquinone conjugates within 24 h ^{1,2Reference 1Schindler et al. · 2002RCTUrinary excretion and metabolism of arbutin after oral administration of Arctostaphylos uvae ursi extract in healthy humans — a randomised crossover pharmacokinetic studyView study →Reference 2Quintus et al. · 2005Urinary excretion of arbutin metabolites after oral administration of bearberry leaf extracts — pharmacokinetic studyView study →}, and the leaf is broadly antibacterial in vitro ^{3,4,5Reference 3Cybulska et al. · 2011In vitroExtracts of Canadian First Nations medicinal plants inhibit Neisseria gonorrhoeae isolates with different antibiotic-resistance profiles — in vitro studyView study →Reference 4Deutch · 2017In vitroLimited effectiveness of over-the-counter plant preparations against the urease of Staphylococcus saprophyticus — in vitro studyView study →Reference 5Dell’Annunziata et al. · 2022In vitroIn vitro antibacterial and anti-inflammatory activity of Arctostaphylos uva-ursi leaf extract against Cutibacterium acnes — in vitro studyView study →}.

The clinical trials are negative: the ATAFUTI factorial RCT (n=382) found no symptom benefit versus placebo ^{6Reference 6Moore et al. · 2019RCTUva-ursi extract and ibuprofen as alternative treatments for uncomplicated urinary tract infection in women (ATAFUTI) — a factorial randomised trial (RCT)View study →}, and the German REGATTA/Gágyor trial (n=398) failed non-inferiority against fosfomycin and produced more pyelonephritis (8 vs 2) ^{7Reference 7Gágyor et al. · 2021RCTHerbal treatment with uva ursi extract versus fosfomycin in women with uncomplicated urinary tract infection in primary care — a double-blind randomised controlled trial (RCT)View study →}. Bearberry is a traditional urinary antiseptic, not a proven cure, and it does not replace antibiotics where an infection is established.